Once given to adolescents, the manufacturer of the COVID-19 vaccine continues to test the effectiveness of the Corona vaccine for younger children. Most recently, Sinovac was claimed to be effective for young children in a phase II trial.
The Global Times reported, as seen on Saturday (24/7/2021) that the Sinovac vaccine in China has undergone Phase II clinical trials for children aged 3-17 years. Sinovac is also allowed for emergency use with small children.
The clinical trial involved 180 volunteers aged 3-17 years. As a result, efficacy data shows that it is 98.9% effective in children, Sinovac announced on Monday.
These results are better than in the population 18 years and older, Sinovac said. They claim this data means their Corona vaccine is stable and effective for young children.
Previously, the WHO in June 2021 had authorized the emergency use of the Sinovac vaccine for ages 18 and older. Efficacy results showed 51% and 100% rates of prevention of severe symptoms and hospitalization in the studied population.
In China, emergency use of Sinovac for children aged 3-17 years began in May 2021. Meanwhile, in July 2021, various cities in China performed COVID-19 immunization for adolescents aged 15-17 years.
Tags
SCIENCES